Quest’s (NYSE:DGX) Q3 2026: beats on revenue

Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 10% year on year to $3.1 billion. The company’s full-year revenue guidance of $12.09 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $3 per share was 4.4% above analysts’ consensus estimates.